Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Jul 21;183(3):549–564. doi: 10.1007/s10549-020-05801-4

Fig. 5. Silencing NRF2 enhances the cytotoxicity of LO.

Fig. 5.

A MDA-MB-231 and GILM2 cells were transfected with siRNAs targeting NRF2 (si1 NRF2 or si2 NRF2) or non-silencing control siRNAs (siC), and NRF2 mRNA levels were measured by RT-PCR 48 hours after transfection. NRF2 mRNA levels are presented as fold change compared to levels in control siRNA-transfected cells. B, TXNRD activity of MDA-MB-231 and GILM2 cells transfected with control (siC) or NRF2 siRNAs (si1 NRF2, si2 NRF2) and cultured in control media in presence or absence of LO (20 ng/ml) for 48 hours. C and D, Crystal violet cell survival assay of MDA-MB-231 (C) and GILM2 (D) cell lines transfected with control (siC) or NRF2 siRNAs (si1 NRF2, si2 NRF2) and cultured in the presence or absence of LO (20 ng/ml) for 48 hours. Left panel: representative images. Right panel: quantification performed by scoring cell confluence in 3 fields of each well (mean ± SEM, n = 3). In all panels, **, P < 0.01, ***, P < 0.001 versus control.